Complex decisions are often challenging. Accurate and actionable prognosis is necessary to choose the best treatment for your patient quickly.

EndoPredict® Breast Cancer Prognostic Test helps to predict each patient’s risk of breast cancer recurrence and chemotherapy benefit. The test combines clinical and molecular factors for greater prognostic power compared with classical prognostic factors alone, or first-generation tests only measuring gene expression.

Precision and clarity for breast cancer treatment

Proven accuracy: EndoPredict® combines the molecular score, tumour size, and nodal status to give more prognostic power than first generation tests, which only measure gene expression.

Informed decisions: With clear, actionable insights from EndoPredict®, you can confidently make well-informed choices.

Personalized treatment: By giving you the individualized chemotherapy benefit for each patient, EndoPredict® enables tailored treatment plans for optimal outcomes.

The EndoPredict® test results give patients an individualized risk score and classifies them into a simple high-risk or low-risk group, with a reliable cut-off value that has never changed. The endpoints of the test are:

Likelihood of distant recurrence within years 0–10

Absolute chemotherapy benefit at 10 years

Likelihood of late distant recurrence within years 5–15

Click here for more details on EndoPredict® Breast Cancer Prognostic Test.